tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Gil Blum, 318 are a BUY (98.15%), 6 are a HOLD (1.85%).
Analyst Gil Blum, currently employed at NEEDHAM, carries an average stock price target met ratio of 21.51% that have a potential upside of 53.67% achieved within 113 days. Previously, Gil Blum worked at TRUIST.
Gil Blumās has documented 618 price targets and ratings displayed on 26 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on SRPT, Sarepta Therapeutics at 03-Apr-2025.
Analyst best performing recommendations are on CTIC (CTI BIOPHARMA CORP).
The best stock recommendation documented was for GTHX (G1 THERAPEUTICS) at 6/25/2024. The price target of $6 was fulfilled within 43 days with a profit of $3.8 (172.73%) receiving and performance score of 40.17.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$2
$0.6 (42.86%)
1 years 3 months 18 days ago
(18-Dec-2023)
0/2 (0%)
$0.7 (53.85%)
Buy
$2
$0.6 (42.86%)
$36
1 years 8 months 23 days ago
(13-Jul-2023)
0/2 (0%)
$0.59 (41.84%)
Hold
$2
$0.6 (42.86%)
$2
1 years 8 months 24 days ago
(12-Jul-2023)
1/3 (33.33%)
$0.57 (39.86%)
7
Buy
2 years 3 months 29 days ago
(07-Dec-2022)
0/2 (0%)
$13.44 (140.59%)
Buy
2 years 10 months 19 days ago
(17-May-2022)
0/1 (0%)
$19.05 (212.85%)
Which stock is Gil Blum is most bullish on?
Which stock is Gil Blum is most reserved on?
What Year was the first public recommendation made by Gil Blum?
